Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Holdings Lifted by Schroder Investment Management Group

Schroder Investment Management Group grew its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 111.2% in the 4th quarter, Holdings Channel reports. The firm owned 156,874 shares of the company’s stock after acquiring an additional 82,601 shares during the quarter. Schroder Investment Management Group’s holdings in Janux Therapeutics were worth $8,236,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in JANX. Avanza Fonder AB bought a new position in shares of Janux Therapeutics during the fourth quarter worth about $139,000. Chicago Capital LLC bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $230,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Janux Therapeutics during the third quarter worth approximately $317,000. Virtu Financial LLC increased its position in Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares during the period. Finally, Legato Capital Management LLC acquired a new position in Janux Therapeutics during the 4th quarter worth $347,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JANX. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Wedbush reissued an “outperform” rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Janux Therapeutics presently has an average rating of “Buy” and an average target price of $92.44.

Janux Therapeutics Trading Down 4.5 %

Shares of JANX opened at $25.77 on Friday. Janux Therapeutics, Inc. has a 1-year low of $24.30 and a 1-year high of $71.71. The stock has a market capitalization of $1.52 billion, a P/E ratio of -22.03 and a beta of 3.23. The business’s 50-day moving average price is $34.09 and its 200 day moving average price is $45.29.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. acquired 110,206 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares of the company’s stock, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $2,640,768.85. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,668 shares of company stock worth $548,183 in the last quarter. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.